Exact Sciences to participate in Canaccord Genuity Medical Technology & Diagnostics Forum

Exact Sciences to participate in Canaccord Genuity Medical Technology & Diagnostics Forum

<0> The Luminis Group, Ltd. for Exact Sciences Corp.Rod Hise, 608-807-4607 </0>

Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will present at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York.

Kevin T. Conroy, Exact’s president and chief executive, will make the company’s presentation at 10 a.m. ET on Tuesday, Dec. 4.

A live webcast of the presentation will be available through the company’s website at . An archive of the webcast will be available following the conclusion of the conference.

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company’s website at .

anticipated results and timing of our pivotal clinical trial, expectations concerning our ability to secure FDA approval of our Cologuard test

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.